Literature DB >> 32057684

Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist.

Francesca Carubbi1, Maria Domenica Cappellini2, Silvia Fargion3, Anna Ludovica Fracanzani4, Fabio Nascimbeni5.   

Abstract

Gaucher disease (GD), a rare lysosomal storage disorder caused by deficient glucocerebrosidase activity and consequent accumulation of glycosphingolipids in the mononuclear phagocyte system, may progress to disabling and potentially life-threatening complications when left undiagnosed and untreated. Unfortunately, because of non-specific signs and symptoms and lack of awareness, patients with type 1 GD, the most common non-neuropathic variant, frequently experience diagnostic delays. Since splenomegaly and thrombocytopenia are the dominant clinical features in many GD patients leading to first medical contact, the hepatologist and the gastroenterologist need to be aware of this condition. Liver involvement has been reported in the majority of GD patients, and comprises hepatomegaly, with or without liver enzymes alteration, fibrosis/cirrhosis, portal hypertension, focal liver lesions, and cholelithiasis. Moreover, GD is associated with several biochemical alterations of potential interest for the hepatologist and the gastroenterologist, including hypergammaglobulinemia, hyperferritinemia and metabolic abnormalities, that may lead to misdiagnoses with chronic liver diseases of common etiology, such as primary hemochromatosis, autoimmune liver diseases or nonalcoholic fatty liver disease. This comprehensive review, based on the collaborative experience of physicians managing patients with GD, provides practical information on the clinical, histological and radiological hepatic manifestations of GD aiming at facilitating the diagnosis of GD for the hepatologist and the gastroenterologist.
Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diagnosis; Glucocerebrosidase deficiency; Liver disease; Splenomegaly

Mesh:

Substances:

Year:  2020        PMID: 32057684     DOI: 10.1016/j.dld.2020.01.004

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Establishment and Phenotypic Analysis of the Novel Gaucher Disease Mouse Model With the Partially Humanized Gba1 Gene and F213I Mutation.

Authors:  Jia-Ni Guo; Ming Guan; Nan Jiang; Na Li; Ya-Jun Li; Jin Zhang; Duan Ma
Journal:  Front Genet       Date:  2022-05-27       Impact factor: 4.772

2.  Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites in Gaucher Disease.

Authors:  Kunal Adhyaru; Sherna Menezes; Pramod K Mistry; Aabha Nagral
Journal:  Cureus       Date:  2022-04-08

Review 3.  Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.

Authors:  Patricia Dubot; Leonardo Astudillo; Nicole Therville; Lorry Carrié; Magali Pettazzoni; David Cheillan; Jérôme Stirnemann; Thierry Levade; Nathalie Andrieu-Abadie; Frédérique Sabourdy
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.